2023
Long-Term Patient Outcomes After Femoropopliteal Peripheral Vascular Intervention in Patients With Intermittent Claudication
Altin S, Parise H, Hess C, Rosenthal N, Creager M, Aronow H, Curtis J. Long-Term Patient Outcomes After Femoropopliteal Peripheral Vascular Intervention in Patients With Intermittent Claudication. JACC Cardiovascular Interventions 2023, 16: 1668-1678. PMID: 37438035, DOI: 10.1016/j.jcin.2023.05.001.Peer-Reviewed Original ResearchMeSH KeywordsFemoral ArteryHumansIntermittent ClaudicationLower ExtremityPopliteal ArteryTreatment OutcomeConceptsPeripheral vascular interventionsIndex limb amputationAmputation rateIntermittent claudicationMajor amputationRevascularization ratesVascular interventionsCox proportional hazards regressionLong-term patient outcomesMajor amputation rateProportional hazards regressionKaplan-Meier estimatesFurther risk factorsLimb amputation rateClinical trial dataIndex limbIC patientsSecondary outcomesPrimary outcomeHazards regressionRisk factorsPatient outcomesLimb amputationHealthcare databasesPatients
2022
Randomized Trial of Chocolate Touch Compared With Lutonix Drug-Coated Balloon in Femoropopliteal Lesions (Chocolate Touch Study)
Shishehbor MH, Zeller T, Werner M, Brodmann M, Parise H, Holden A, Lichtenberg M, Parikh SA, Kashyap VS, Pietras C, Tirziu D, Ardakani S, Beschorner U, Krishnan P, Niazi KA, Wali AU, Lansky AJ. Randomized Trial of Chocolate Touch Compared With Lutonix Drug-Coated Balloon in Femoropopliteal Lesions (Chocolate Touch Study). Circulation 2022, 145: 1645-1654. PMID: 35377157, DOI: 10.1161/circulationaha.122.059646.Peer-Reviewed Original ResearchConceptsLutonix drug-coated balloonDrug-coated balloonsEnd pointPrimary efficacy end pointPrimary safety end pointIndependent clinical events committeeIschemic rest painPrimary efficacy rateEfficacy end pointPrimary end pointSafety end pointClinical events committeeMajor adverse eventsRate of restenosisDrug-Coated BalloonNoninferiority end pointSafety event rateAverage lesion lengthMajor amputationPopliteal diseaseRest painBailout stentingEfficacy ratePrimary patencyAdverse events